Women's Health Research Is Finally Getting Its Own Home at NIH
Why this news matters to me
On October 19, 2026, the federal government ordered the National Institutes of Health to create a division dedicated to women's health. I have been waiting a long time for a headline like this.
I began my journey as a women’s health nurse practitioner in 2011 and focusing on menopause care in 2017 because I kept seeing the same pattern in my patients: real symptoms, real suffering, and very few answers in my training. For years I have been making the case that women's health deserves its own science, not a footnote in research built around men. This announcement is a step toward that, and I want you to know exactly what it does and does not do.
What was announced
An executive order titled Advancing Women's Health to Improve Outcomes in All Phases of Life was signed on October 19, 2026. It does two main things.
A new Women's Health Division at NIH. NIH has 90 days to set it up within one of its institutes or centers. It will work alongside the existing NIH Office of Research on Women's Health.
A White House Women's Health Task Force. It is co-chaired by the Secretary of Health and Human Services and the White House Chief of Staff, with leaders from agencies including the FDA, CDC, and NIH.
The new division is charged with increasing scientific review of understudied conditions, coordinating research, increasing the number of women in clinical trials, and getting findings into everyday care faster (Contemporary OB/GYN).
The order names many conditions that need more research, including heart disease, cancer, stroke, Alzheimer's disease, autoimmune and inflammatory conditions, osteoporosis, mental health, chronic pain, endometriosis, fibroids, PCOS (now renamed polyendocrine metabolic ovary syndrome), infertility, maternal health, and menopause (White House).
Why this matters: women were left out for decades!
For much of modern medicine, research was designed around men and the results were applied to women. That is not an opinion. It is in the federal record.
| Year | What happened |
| 1977 | The FDA recommended excluding women of childbearing potential from early drug trials, including women using contraception (NIH ORWH). |
| 1990 | A federal audit found NIH's policy to include women in research was poorly communicated and inconsistently applied. NIH created its Office of Research on Women's Health two months later (NIH ORWH). |
| 1993 | Congress made including women in NIH clinical research federal law through the NIH Revitalization Act (NIH ORWH). The FDA rescinded its 1977 guideline the same year (SWHR). |
| 2001 | A government report found that 8 of the 10 prescription drugs pulled from the market since 1997 posed greater health risks for women than for men. For four, women may simply have been prescribed the drug more often; the other four caused more harm in women even though both sexes used them widely (GAO-01-286R). |
| 2013 | The FDA set a lower recommended starting dose of the sleep drug zolpidem (Ambien) for women: 5 mg, versus 5 or 10 mg for men, because of the risk of next-morning impairment (FDA). |
| 2016 | NIH began expecting researchers to account for sex as a biological variable in the animal and human studies it funds (NIH ORWH). |
| 2024 | The National Academies found that just 8.8% of NIH grant spending from 2013 to 2023 went to women's health research. It also found that menopause, endometriosis, and fibroids are not prioritized by any of NIH's 27 institutes and centers (National Academies). |
| 2026 | An executive order directed NIH to create a Women's Health Division within 90 days (White House). |
Think about the zolpidem example: a widely prescribed sleep medication did not have a women-specific starting dose until 2013. Progress has been real. Still, the National Academies found that conditions like endometriosis and fibroids affect millions of women while physicians lack clear guidance, and that major knowledge gaps remain about menopause.
Maybe testosterone dosages, appropriate for women, will be next!
What ACOG and its partners said
The American College of Obstetricians and Gynecologists (ACOG), the Society for Women's Health Research (SWHR), and the Women First Research Coalition (WFRC) welcomed the order in a joint statement on October 19, 2026. They said it complements their National Strategy to Close the Women's Health Gap, which is backed by nearly 80 national organizations and calls for a $20 billion investment over 10 years (Contemporary OB/GYN).
They were also clear about what comes next. The groups stated that "robust and sustained funding is necessary" for this to improve women's health, and asked that the effort be appropriately resourced.
That point matters. The order sets no specific funding amount, and carrying it out depends on available appropriations. A new division is a structure. Funding is what turns it into studies, and studies are what turn into better care.
Who is backing this
On the day the order was signed, leading women's health organizations publicly welcomed it.
ACOG, SWHR, and the Women First Research Coalition issued a joint statement welcoming the order and calling for robust, sustained funding (Contemporary OB/GYN).
The Endocrine Society issued its own statement the same day, naming gaps in understanding of conditions including polyendocrine metabolic ovary syndrome (PCOS), menopause, infertility, osteoporosis, and thyroid disorders (Endocrine Society).
The National Strategy to Close the Women's Health Gap, which these groups said the order complements, is backed by nearly 80 national organizations and calls for a $20 billion investment over 10 years (Contemporary OB/GYN).
SWHR has worked on this since 1990. It was founded that year to advocate for including women in research, helped request the 1990 federal audit of NIH, and says the 1993 law requiring women in NIH research was written with its input (SWHR history).
What this means for you right now
Research takes years, so nothing about your care changes this week. Here is what you can do today:
Trust what you are feeling. If something feels off, it deserves a real conversation, not a brush-off.
Ask how a treatment was studied in women. It is a fair question to ask.
Consider a clinical trial. More women in studies means better answers for all of us. ClinicalTrials.gov lists studies you can search.
Bring your questions to us. Whether it is perimenopause, menopause, painful periods, fibroids, or something you have been told is "just normal," we will take the time to listen and walk through your options, in our Boise office or by telehealth across Idaho and Montana.
Menopause, endometriosis, fibroids, and the rest are not trends, and they are not in your head. They are real, measurable, biological conditions. The science we have is real too. What it needs now is more research, more funding, and more attention. Women deserve answers, and I am glad to see the science finally being asked to catch up.
The timing could not be better. As this news broke, I was boarding a flight to The Menopause Society Annual Meeting, where clinicians and researchers gather to share the newest evidence in midlife women's health. I am going to learn, ask hard questions, and bring what I learn home to our whole team and to you. And now I’m writing this blog post while in the air (shout out to Alaska Airlines for the free WiFi). From all of us at Illumination Women's Health: we've got you, ladies.
